Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts

Metformin (MET) is a diabetes drug that activates AMP‐activated protein kinase (AMPK), and is suggested to have anticancer efficacy. Here, we investigated the role of AMPK signalling in prolactinoma (PRLoma), with particular respect to MET and bromocriptine (BC) as a PRLoma treatment. We analysed AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jun, Liu, Yang, Han, Gaijing, Deng, Kan, Liu, Xiaohai, Bao, Xinjie, Feng, Ming, Yao, Yong, Lian, Wei, Xing, Bing, Lv, Xiang, Wang, Renzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237574/
https://www.ncbi.nlm.nih.gov/pubmed/30334324
http://dx.doi.org/10.1111/jcmm.13963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237574/
https://www.ncbi.nlm.nih.gov/pubmed/30334324
http://dx.doi.org/10.1111/jcmm.13963

Ejemplares similares